Douglas to keep it in the family after considering bids
This article was originally published in Scrip
Companies looking to expand their presence in New Zealand through acquisitions can strike off their lists of prospects the most obvious target - the country's largest home-grown pharma firm, Douglas Pharmaceuticals.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.